Quarterly review – Changes to Prime Funds, Prime ETFs & Prime Portfolios

Prime Funds is our list of recommendations in equity, debt, and hybrid mutual funds that are worth investing in. Prime Funds narrows down your choices from the thousands of funds that there are into a concise list of funds that span different styles. Prime Funds are selected based on performance, portfolios, and investment strategies. 

In this review, we have made a few changes in multiple Prime Funds categories. Please go through the report in detail to know the changes and the rationale.

About Prime Funds

Prime Funds is our list of best mutual funds across the equity, debt, and hybrid categories. We use Prime Ratings, our fund ratings, as a first filter. We then apply qualitative analysis to arrive at our fund recommendations. Prime Funds is an enduring list of funds that you can use at any time. You will always find a fund to meet any goal you’re looking to meet.

Different categories: Prime Funds are separated into buckets, based on risk level in equity & hybrid funds and timeframe in debt funds. Each of these draws from different SEBI-defined categories. We have classified them in a more user-friendly way than using the several dozens of SEBI categories. We do not go only by Prime Ratings but look at other factors as well to narrow the list and make the choices easy for you.

Different styles: In Prime Funds, we’ve aimed at providing funds that follow different strategies for you to mix styles and diversify your portfolio with ease. The ‘Why this fund’ for each Prime Fund will brief its strategy, why we picked it, and how to use it in your portfolio.

Direct plans: We have specifically given the direct plans in Prime Funds. If you wish to know whether it is ok for you to use the regular plan of the fund, check  Portfolio Review Pro  periodically to know if you are with expensive regular plans.

Quarterly review: Our aim in reviewing the Prime Funds list every quarter is to ensure that we don’t miss any good opportunities that are coming up and we are not holding on to funds that are slipping. When we remove funds from the Prime Funds list, we tell you exactly what to do if you have invested in these funds. Funds we remove do not immediately call for a sell – it is just that they have slipped in performance marginally or there are better alternatives now. Unless our review tool says such funds are a ‘sell’, you can hold them (refer to our article on when to sell funds)

Using Prime Funds: You don’t need to hold every Prime Fund nor add every new fund we introduce to the list. Unless it fits your overall portfolio/strategy, or there is something lacking, there is little need for you to go on adding funds. Our idea of covering them in detail through some of our calls is to let you know the strategy, style, and suitability in different portfolios. It is not a specific call to buy right away, unless we mention that it is a ‘tactical’ or ‘timing’ call. If you need to build a portfolio using Prime Funds, use our Build Your Own Portfolio tool to make this easy for you.

Equity

The past six months have witnessed a healthy correction across all market cap segments in India. While the September-December quarter was already challenged by FII (Foreign Institutional Investors) outflows, moderating corporate earnings, and slowing GDP growth, the situation intensified with new tariff announcements from President Trump’s administration. 

During this 6-month period, the Nifty 50 declined nearly 10%, the Midcap 150 fell 15%, and the Smallcap 250 dropped 19%. However, a pullback has emerged over the past month, with FIIs turning net buyers in March 2025 after a five-month absence. This correction has provided fund managers and analysts valuable opportunities to acquire premium stocks at more reasonable valuations while also helping distinguish between flashy performers and steady performers in the MF space. 

At PrimeInvestor, we will be offering a combination of funds and stocks that can possibly ride this pullback and participate in a new wave of market trend. While we remain cautious in some of the spaces that have corrected, we do see opportunities in the large-cap and mid-cap space. We also do not fail to spot the next thematic opportunity in the market. Our changes in Prime Equity funds seek to achieve the above. 

In this set, we have added one more aggressive fund from the pure midcap category – Motilal Oswal Midcap. Unlike some of our other midcap funds, this fund has a clear growth strategy.  The fund looks for companies with growth potential in industries where large-caps may not be found. 

Examples include sectors such as hospitality, agriculture-related products, or defence. It seeks to hold a very compact portfolio of under 35 stocks and applies its QGLP (quality, growth, longevity price) formula to filter stocks. It deviates a good bit from the Nifty Midcap index, in terms of sector exposure, to deliver returns. 

The fund is among the most consistent performers in the midcap set, with steady category-beating rolling 1-and -3-year returns. It manages this even as it contains downside better than the category in market falls. The fund has limited overlap with our midcap funds in Prime Funds and also has differentiated sector-overweight positions. It can therefore be paired with any of them if you are looking to diversify midcap exposure.

Entry: The fund can be paired with passive funds or any of our current moderate risk Prime Funds. Use SIP for any fresh exposure now. Make sure you do not go overboard on mid or small-cap segments in your overall portfolio allocation.

We would also like to mention that HDFC Smallcap – which has been underperforming for close to 11 months now – is seeing the margin of underperformance over peers narrowing. It has also evened out in returns when compared to the index. The fund remains in our list and we are closing watching for further improvement. 

We had introduced this Prime Funds set in March last year. The intent was to pick up funds that were markedly outperforming, but where such performance was not solidly established in long-term periods. The idea was to latch on to higher returns that such turnarounds provide. 

The risk in this category is that the fund is unable to firmly establish outperformance, especially in adverse market conditions. This is playing out now with JM Value. We had added this extremely aggressive fund in our March quarter review last year. 

JM Value has in the past few weeks begun to lag the Nifty 500 TRI on a 1-year return basis; this is currently a small margin. However, looking at much shorter-term returns of 1 month or 3 months serves to show the impact of a market correction. JM Value has been steadily behind the Nifty 500 TRI by about 2 percentage points on a 1-month basis. The fund’s 30%-plus holding in smallcaps has especially hurt. The fund has also not bounced back as much as the index in the recent market rebound.

Given the nature of this Prime Funds category, it is necessary for us to be nimbler with our calls here and stricter over underperformance. Therefore, we are pulling JM Value out of Prime Funds. 

Action to take: Stop all SIPs and any fresh investments in the fund. Existing investments made can be retained and there is no need to exit. The fund’s higher exposure to financials, consumer stocks, and auto can help it return to performance as these segments have also been out of market favour. Based on market and fund performance, we will issue a Sell call if necessary.

We have been regularly identifying themes/sectors that are about to take off and also recommend book profits in opportunities that have reasonably delivered. Many of our calls including in pharma and technology have delivered well. 

We are now adding ICICI Prudential Commodities fund. This is not the first time we are recommending this theme. We had recommended a book profit and hold on this theme last year. We are now once again recommending a lumpsum investment with limited exposure to this fund. The fund has a mix of metals, chemicals and cement. 

While the global outlook for metals remains stable, locally, Indian steelmakers could see room for price increases on hot rolled steel products if the proposed 12% safeguard duty on flat steel imports is imposed. Chemicals too, after bottoming out, are seeing some signs of recovery. The chemical sector rallied after US distributors announced refrigerant gas price increases of up to 200%, citing supply shortages. This development has created optimism in the chemical industry, as experts believe Indian specialty chemical companies could see significant EBITDA improvements from even small increases in gas price realizations. 

Entry: The fund is a high-risk option and is only for investors who are willing to take significant volatility. Exposure should be limited and investment is recommended as small lumpsum now. Those who already hold the fund need not average it now. 

Debt

The Reserve Bank finally initiated the rate cut cycle in its February policy. However, as we had mentioned in our 2025 debt outlook, markets had priced in rate cuts well before the actual event. Longer-maturity debt funds, gilt funds, and constant maturity funds have all clocked strong returns.

Returns for other accrual debt fund categories have also picked up as portfolio yields improved. With limited room left in a duration play, we have looked at funds from the perspective of yields and return potential through accrual.

On this front, funds we have in all the Prime Funds debt categories are all well-positioned and are those that have steadily delivered above-average returns. There are no new funds that we can add that offer any differentiation or return potential. 

We are making just one change in the debt Prime Funds, as explained below.

In this set, we are removing ICICI Pru Banking and PSU Debt. We had added this fund in September 2023 as a short-to-medium term duration play and owing to its deft strategies in shifting maturities and using instruments such as floating rate bonds to squeeze more returns from the prevailing market cycle. 

With the window for a duration strategy now closing, the fund’s portfolio and strategy will have a limited role to play compared to the other corporate bond funds in this Prime Funds category. The ICICI fund’s returns have also been slipping marginally behind its peers in recent times, owing to its longer maturity. 

Action to take: Retain all existing investments made in the fund, especially if you had invested in it with a 2-3 year perspective. Exit when your goal is reached. Fresh investments can be made in any of the corporate bond funds in this Prime Funds set.

Prime ETFs

Prime ETFs is our list of recommended ETFs in equity, debt, and gold. We look at multiple factors to draw up this list, ranging from short-term and long-term tracking error, expense ratio, trading volumes and usefulness of the index in a portfolio. 

In this review, we are making two changes as follows:

In this Prime ETF category. we are removing SBI S&P BSE Sensex. In its place, we are adding ICICI Pru BSE Sensex ETF. 

ETFs tracking BSE indices typically have lower trading volumes than NSE indices. The SBI ETF was among those that had reasonable trading volumes and lower tracking error. However, the ICICI Pru ETF has seen a better volume improvement than the SBI ETF. Its average daily trading volume now stands at about Rs 1.64 crore compared to the Rs 63 lakh that the SBI ETF had. Its tracking error is in line with other Nifty 50 ETFs and similar to the SBI Sensex ETF.

Action to take: If you have invested in the SBI Sensex ETF, continue with it for existing and future investments. There is no need to switch to the ICICI Pru ETF. Its tracking error compared to the underlying index is low and deviation between market price and NAV is also lower. As explained above, the only reason we are making the change is that it had comparatively lower volumes.

Entry: For those looking to add the ICICI Pru Sensex ETF, it can be used for large-cap exposure in your portfolio. Avoid holding both this and a Nifty 50 ETF as both return similarly.

In this Prime ETF category, we are removing ICICI Pru Nifty Private Bank ETF and replacing it with Mirae Asset Nifty Financial Services ETF. 

The Nifty Financial Services index tracks the performance of India’s financial market by including companies from six subsectors: banking, financial institutions, housing finance, NBFC, insurance, and other financial services. The index plays two opportunities – one, the bank opportunity with private banks holding a heavy portfolio weight. Two, other opportunities in the financials space which a pure bank index will be unable to achieve. In the current scenario, a broader play on the financials space would serve better than a narrow private-bank-only option. The Mirae ETF has healthy trading volumes and low tracking error.

Action to take: If you have already invested in the ICICI Pru Private Bank ETF, you can continue to remain invested.

Entry: Those who want to invest in the Mirae Financial Services ETF can invest in multiple lumpsums using dips. Note that this is a high-risk thematic ETF. Keep exposure limited to 10% of your portfolio.

In this ETF set, we are removing SBI Gold ETF from the list. This is simply because we already have Nippon India ETF Gold BeES in the list and we want to avoid the confusion and duplication of having two gold ETFs. We have gone with the ETF that had higher volumes.

Action to take: If you have already invested in the SBI Gold ETF, remain invested. You can continue with any SIPs you have in this ETF as well. The ETF remains good on tracking error and there is no necessity to make any changes here.

Prime Portfolios

In this review, we are making no fund changes in any portfolio.

However, in Prime Portfolios, we tell you what action to take on funds that have been part of a portfolio before where we have given a Hold call. In this review, we want to issue such action on portfolios that contained Nifty Next 50 index funds/ETFs and Axis Banking & PSU Debt Fund.

  • We had given a hold on both the NIfty Next 50 index funds and ETF in various portfolios in our review post March 2023. We are now giving an exit call merely to make the portfolios more compact and reduce the size of the portfolios. Our call on the index remains a ‘hold’. This is merely a call to consolidate the portfolio. We have recommended alternatives below to reinvest the amount received as lumpsum into different funds mentioned. 
  • We have given a ‘Sell’ call on Axis Banking & PSU Debt fund considering its lower than category average returns and yield to maturity (YTM). This fund was moved to a hold in our 3-5 year portfolio (moved to hold in our June 2023 review) and 5-7 year portfolio (moved to hold in our December 2023 review). Now with the fund being moved to a sell, you can exit the fund from the above portfolios. We have recommended alternatives below to reinvest the amount received as lumpsum into different funds mentioned.

Please note that these funds would not have appeared for those who followed this portfolio after we moved them to a hold. Hence, no action is needed for such investors who did not hold it in the first place.

You can view the full list of Prime Funds here.

You can view the full list of Prime ETFs here.

You can view the full list of Prime Portfolios here.

Disclosures & Disclaimers

More like this

12 thoughts on “Quarterly review – Changes to Prime Funds, Prime ETFs & Prime Portfolios”

  1. daniel.emmett774

    Why is HDFC Midcap opportunities not in the prime funds category even through its a 5* fund and has better track record of long term performance and also good fund manager who has been managing it since 16 years?

    1. Bhavana Acharya

      The midcap funds we have in Prime Funds are quality, consistent performers. We do not have every top-rated fund in Prime Funds; our aim in Prime Funds is to keep the list concise and as diverse as possible in terms of fund style. Unless the funds we have in Prime Funds are faltering, or other funds outstrip them significantly, we do not change the list as it would introduce unnecessary churn in investor portfolios. In this case, HDFC Midcap Opps is a good performer, but its not a big enough outperformer for us to replace the existing Prime funds. – thanks, Bhavana

  2. IT Sector funds- could have been a sell Call in March 2025. not saying this based on hindsight, but after seeing few research reports view on IT sector/US etc.

    1. It has fallen the most year to date. At such reasonable valuations, even a sedate earnings is ok. It is always a question of valuation vs growth in our view. If US goes into a further slowdown if it screws up on tariff, we have to see the prospects for IT then. For now, we expect a bounce back.

      1. Thanks Vidya. However this didn’t answer the original question as to why there is no proactive call to sell, as much there is for a buy. IT valuations has got super expensive except for the top 3 to4, there was a time when the PEs were above historical avgs. Especially mid cap IT

        1. We have to be specific. Most IT funds have a large portion in top tier. So oevrall they will be reasonable. Also in mid-tier there has been significant correction and have come beloe median PEs. Of coursr there could be exceptions. So the super expensive term has to be seen in relation to newer areas of growth. In such a market, we prefer the large ones and our Prime Stocks is reflective of this. But yes, we are watching the secondary effect on US slowdown on IT sector. It will take few months to knwo this. Vidya

    1. Bhavana Acharya

      No, it is not recommended to switch from Mahindra Midcap to Motilal Midcap. The former is still a Prime Fund and a strong performer. – thanks, Bhavana

  3. nikhil.abhyankar

    1. Why have volatile funds like next 50 or midcap in a 3 to 5 year portfolio?

    2. “The ICICI fund’s returns have also been slipping marginally behind its peers in recent times, owing to its longer maturity.”

    Is the longer maturity an issue only with this sector (banking) and this time frame (3-5 years)? We are holding other funds with long(er) maturities in view of rate cuts. Would they have any impact?

    1. Bhavana Acharya

      1. Midcaps are there to give some leg up to returns; the remaining portfolio is conservative enough to accommodate any volatility.
      2. As explained in the review, we had given the ICICI fund more as a tactical call. In that Prime Funds category, it shares similarities with the other funds and therefore we have removed it. It’s fine to remain invested in this and other longer maturity funds. – thanks, Bhavana

    1. Bhavana Acharya

      No, we do not recommend switching from Kotak to Motilal. The Kotak fund is still a quality, consistent long-term outperformer with excellent downside containment ability. The Kotak fund is still part of Prime Funds. – thanks, Bhavana

Leave a Comment

Hold On

You are being redirected to another page,
it may take a few seconds.
Login to your account
OR

Become a PrimeInvestor!

Get stock & mutual fund recommendations

Start registration

OR
user icon
user icon
user icon

Terms & Conditions

A copy of the T&C has been sent to your email.

Last modified on February 18, 2025

This website www.primeinvestor.in (“Website”) is owned and operated by PrimeInvestor Financial Research Pvt. Ltd. (“RA”), a SEBI-registered Research Analyst with Registration No. INH200008653.

Through the Website, the RA allows clients to access research recommendations, research reports, and model portfolios, along with tools, personal finance products, and articles, on the payment of a subscription fee (“Research Services”). The terms ‘RA’ or ‘us’ or ‘we’ refer to PrimeInvestor Financial Research Pvt Ltd (SEBI RA Registration No INH200008653) who are the owners of this Website and offering the Research Services. The term ‘you’ and ‘client’ refers to the subscriber of the Services on the Website. The RA provides the Research Services subject to the notices, terms, and conditions set forth in these Terms. By accepting these Terms when you subscribe to the Research Services, you provide your consent to abide by these Terms.

Most Important Terms and Conditions (MITC)

[Forming part of the Terms and Conditions for providing research services]

  1. These terms and conditions, and consent thereon are for the research services provided by the Research Analyst (RA) and RA cannot execute/carry out any trade (purchase/sell transaction) on behalf of the client. Thus, the clients are advised not to permit RA to execute any trade on their behalf.
  2. The fee charged by RA to the client will be subject to the maximum amount prescribed by SEBI/ Research Analyst Administration and Supervisory Body (RAASB) from time to time (applicable only for Individual and HUF Clients).
    Note:
    • SEBI's current cap on fee is Rs 1,51,000/- per annum per family of client for all research services of the RA.
    • The fee limit does not include statutory charges.
    • The fee limits do not apply to a non-individual client / accredited investor.
  3. RA may charge fees in advance if agreed by the client. Such advance shall not exceed the period stipulated by SEBI; presently it is one quarter. In case of pre-mature termination of the RA services by either the client or the RA, the client shall be entitled to seek refund of proportionate fees only for the unexpired period.
  4. Fees to RA may be paid by the client through any of the specified modes like cheque, online bank transfer, UPI, etc. Cash payment is not allowed. Optionally the client can make payments through Centralized Fee Collection Mechanism (CeFCoM) managed by BSE Limited (i.e. currently recognized RAASB).
  5. The RA is required to abide by the applicable regulations/ circulars/ directions specified by SEBI and RAASB from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. The RA will endeavor to promptly inform the client of any conflict of interest that may affect the services being rendered to the client.
  6. Any assured/guaranteed/fixed returns schemes or any other schemes of similar nature are prohibited by law. No scheme of this nature shall be offered to the client by the RA.
  7. The RA cannot guarantee returns, profits, accuracy, or risk-free investments from the use of the RA's research services. All opinions, projections, estimates of the RA are based on the analysis of available data under certain assumptions as of the date of preparation/publication of research report.
  8. Any investment made based on recommendations in research reports are subject to market risks, and recommendations do not provide any assurance of returns. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report. Any reliance placed on the research report provided by the RA shall be as per the client's own judgement and assessment of the conclusions contained in the research report.
  9. The SEBI registration, Enlistment with RAASB, and NISM certification do not guarantee the performance of the RA or assure any returns to the client.
  10. For any grievances,
    • Step 1: the client should first contact the RA using the details on its website or following contact details:
      Customer care: [email protected]
      Grievance officer: [email protected], ATTN: Srikanth Meenakshi
      Compliance officer: [email protected], ATTN.: Bhavana Acharya
      Principal officer: [email protected], ATTN.: Vidya Bala
    • Step 2: If the resolution is unsatisfactory, the client can also lodge grievances through SEBI's SCORES platform at www.scores.sebi.gov.in
    • Step 3: The client may also consider the Online Dispute Resolution (ODR) through the Smart ODR portal at https://smartodr.in
  11. Clients are required to keep contact details, including email id and mobile number/s updated with the RA at all times.
  12. The RA shall never ask for the client’s login credentials and OTPs for the client’s Trading Account, Demat Account, and Bank Account. Never share such information with anyone including RA.

By browsing, viewing, using the Website and subscribing to the Research Services provided therein you consent to and agree to comply with these Terms and Conditions of subscription (“Terms”).

The RA reserves the right to change or modify the Website, the contents thereof and these Terms at any time. All modifications to these Terms & Conditions will be posted on the Website and will become effective immediately upon such posting. Changes once made will be communicated to the client. Continued use of the Website shall be construed as acceptance of the revisions to the Terms by conduct.

The following terms and conditions include but are not limited to minimum mandatory terms and conditions to clients as stipulated by SEBI.

1. Availing the research services

By accepting delivery of the research service, the client confirms that he/she has elected to subscribe to the research service of the RA at his/her sole discretion. The RA confirms that Research Services shall be rendered in accordance with the applicable provisions of the SEBI RA Regulations.

2. Obligations on RA

The RA shall be bound by the SEBI Act and all the applicable rules and regulations of SEBI, including the RA Regulations and relevant notifications of Government, as may be in force, from time to time.

3. Client Information and KYC

The client shall furnish all such details in full as may be required by the RA in its standard form with supporting details, if required, as may be made mandatory by Research Analyst Administration and Supervisory Body(RAASB)/SEBI from time to time. RA shall collect, store, upload and check KYC records of the clients with KYC Registration Agency (KRA) as specified by SEBI from time to time.

4. Standard Terms of Service

The consent of client shall be taken on the following understanding:

“I / We have read and understood the terms and conditions applicable to a research analyst as defined under regulation 2(1)(u) of the SEBI (Research Analyst) Regulations, 2014, including the fee structure.

I/We are subscribing to the research services for our own benefits and consumption, and any reliance placed on the research report provided by research analyst shall be as per our own judgement and assessment of the conclusions contained in the research report.

I/We understand that –

  1. Any investment made based on the recommendations in the research report are subject to market risk.
  2. Recommendations in the research report do not provide any assurance of returns.
  3. There is no recourse to claim any losses incurred on the investments made based on the recommendations in the research report.”

The declaration of the RA is as follows:

  1. We are duly registered with SEBI as an RA pursuant to the SEBI (Research Analysts) Regulations, 2014 and our registration details are: registration no SEBI INH200008653, with registration date 19th August, 2021
  2. We have the registration and qualifications required to render the services contemplated under the RA Regulations, and the same are valid and subsisting;
  3. Research analyst services provided by us do not conflict with or violate any provision of law, rule or regulation, contract, or other instrument to which it is a party or to which any of its property is or may be subject;
  4. The maximum fee that may be charged by the RA is ₹1.51 lakhs per annum per family of client. Our current fee structure, the term and duration of our subscription for our Research Services, can be viewed on our website here: https://primeinvestor.in/prime-pricing
  5. The recommendations provided by us as part of the Research Services do not provide any assurance of returns.

5. Consideration and mode of payment

The client shall duly pay to the RA the agreed fees for the services that RA renders to the client and statutory charges, as applicable. Such fees and statutory charges shall be payable through the specified manner and mode(s)/ mechanism(s).

The payment of fees shall be through a mode that shows traceability of funds. Such modes include but are not limited to credit cards/debit cards/ UPI/ net banking or any other mode specified by SEBI from time to time. However, the fees shall not be in cash.

6. Risk factors

  1. Investments are subject to market risk. Investing or trading in financial products involves risk. Past performance of the recommendation is not an indication of future returns. Past performance of the RA is not an indicator of future performance. Past performance of the security is not an indication of future returns.
  2. There are no assurances or guarantees that the objectives of any investment in financial products will be achieved.
  3. The names of financial products mentioned herein do not in any manner indicate their prospects or returns. The performance in the equity may be adversely affected by the performance of individual companies, changes in the market place and industry specific and macro-economic factors.
  4. The performance of the investments/ products recommended by the RA are subject to a wide range of risks, including but not limited to: performance of the respective companies, changes in equity and debt market conditions, micro and macro factors and forces affecting equity and debt markets, general levels of interest rates and interest rate risk, credit risk, liquidity risk, reinvestment risk, economic slowdown, volatility & illiquidity of the stocks, risks associated with trading volumes, liquidity and settlement systems in equity and debt markets and/or such other circumstance beyond the control of the RA or any of its Associates.
  5. Other risk factors include that may affect the performance of the investments/ products recommended by the RA include but are not limited to economic policies, changes of Government and its policies, acts of God, acts of war, civil disturbance, sovereign action and /or such other acts/ circumstance beyond the control of the RA or any of its Associates.
  6. The recommendations provided by the RA as part of its Research Services may not be suitable to all categories of investors.
  7. The client should read all scheme and security related documents carefully before investing.
  8. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

7. Conflict of interest

The RA shall adhere to the applicable regulations/ circulars/directions specified by SEBI from time to time in relation to disclosure and mitigation of any actual or potential conflict of interest. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

General disclosures: PrimeInvestor Financial Research Pvt Ltd (with brand name PrimeInvestor) is an independent research entity offering research services on personal finance products to customers. We are a SEBI registered Research Analyst (Registration: INH200008653). PrimeInvestor Financial Research Pvt. Ltd., its employees, directors or agents, do not have any material adverse disciplinary history as on the date of publication of this report.

Restrictions on trading: To ensure no conflict of interest, the RA declares as follows:

  1. Personal trading activities of the individuals employed as research analysts shall be monitored, recorded and subject to a formal approval by the directors or compliance officer of PrimeInvestor Financial Research Private Limited.
  2. Research analysts employed by PrimeInvestor Financial Research Private Limited or their associates or relatives shall not:
    • Deal/ trade in stocks recommended/ tracked by the research analyst within 30 days before and five days after the publication of a research report;
    • Deal/ trade in securities that the research analyst reviews in a manner contrary to the given recommendation;
    • Purchase or receive securities of the issuer before the issuer's initial public offering, if the issuer is principally engaged in the same types of business as companies that the research analyst follows or recommends.

Disclosures with respect to Research and Recommendations Services:

  1. The RA or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation.
  2. The RA, or any of its officers, directors, employees, or subsidiaries have not received any compensation/ benefits whether monetary or in kind, from the AMC, company, government, bank or any other product manufacturer or third party, whose products are the subject of its Research Services or investment information.
  3. The Research Analysts who have prepared the research reports that form part of the Research Services (“Research Analyst”) certify that all of the views expressed in the research report accurately reflect their views about the subject company or subject security.
  4. The RA or directors or employees or Research Analyst certify that no part of their compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.
  5. The Research Analyst has not served as director, officer or employee in the subject company, AMC or insurance company of the mutual fund or insurance policy that is the subject of this report, or company whose bonds, NCDs, fixed deposits or other savings products that is the subject of this report.
  6. The Research Analyst or their relatives do not have any known direct or indirect material conflict of interest including long/short positions in the subject company.
  7. The Research Analyst may hold investments in the stocks, mutual fund schemes, bonds, fixed deposits, insurance policies, or other products that are the subject of the recommendations provided as part of the Research Services. The Research Analyst certifies that they will not act in a manner contrary to their views on these securities except in the event of significant news or event or change in personal financial circumstances and without formal approval from the directors of PrimeInvestor Financial Research Pvt. Ltd. or the compliance officer.
  8. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of the Research Services. Such conflict of interest shall be disclosed to the client as and when they arise.
  9. The RA or its directors or its employee or its associates have not managed or co-managed the public offering of any company. The RA or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. The RA or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. The RA or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation.
  10. The subject company of its research recommendations was not a client of the RA or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided.
  11. The RA or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.

PrimeInvestor Financial Research Pvt. Ltd., its Associates, the Research Analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies)? – NO

8. Termination of service and refund of fees:

The RA may terminate or suspend rendering of Research Services to the client in the following circumstances:

  1. On account of suspension/cancellation of registration of RA by SEBI. In case of suspension of certificate of registration of the RA for more than 60 (sixty) days or cancellation of the RA registration, RA shall refund the fees, on a pro rata basis for the period from the effective date of cancellation/ suspension to end of the client’s subscription period.
  2. The RA voluntarily chooses to terminate its Research Service. In the event of such termination of the Research Service, the RA shall refund the fees, on a pro rata basis for the period from the date of such termination of research service to end of the client’s subscription period.

9. Grievance redressal and dispute resolution:

Any grievance related to:

  1. nonreceipt of research report, or
  2. missing pages or inability to download the entire report, or
  3. any other deficiency in the research services provided by RA

shall be escalated promptly by the client to the person/employee designated by RA, in this behalf as under:

Name: Bhavana Acharya
Designation: Director & Compliance Officer, PrimeInvestor Financial Research Pvt Ltd
Email: [email protected]

The RA shall be responsible to resolve grievances within 7 (seven) business working days or such timelines as may be specified by SEBI under the RA Regulations.

RA shall redress grievances of the client in a timely and transparent manner. Any dispute between the RA and his client may be resolved through arbitration or through any other modes or mechanism as specified by SEBI from time to time.

If the client is not satisfied with the response of the RA, he/she can lodge his/her grievances with SEBI at scores.sebi.gov.in. Alternatively, the client may also write to any of the offices of SEBI. For any queries, feedback or assistance, please contact SEBI Office on Toll Free Helpline at 1800 22 7575 / 1800 266 7575

Details on grievances are available on the Website as follows: https://primeinvestor.in/ra-grievance/

10. Additional clauses:

Scope of the Research Service: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Services are not meant to be tailor-made or customized solutions that specifically apply to each client based on his/her risk profile.

The RA never guarantees the returns on the recommendation provided. Investor shall take note that investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The RA shall not be responsible for any loss to the Investors.

This service is not directed for access or use by anyone in a country, especially the USA, Canada or the European Union countries, where such use or access is unlawful or which may subject PrimeInvestor Financial Research Pvt Ltd or its affiliates to any registration or licensing requirement.

The Research Service, including recommendations, research reports, updates, and other information will be accessible through the RA’s website https://primeinvestor.in only. Such recommendations and updates will not be provided over phone calls.

Fees: Our current fee structure, the term and duration of our subscription for our Research Service, can be viewed on our website: https://primeinvestor.in/prime-pricing. Eligibility for any discounts is ascertained at the time the client subscribes. Any such discount and its tenure shall be at the discretion of the RA.

Subscription and access to content services fall under the purview of Goods and Services Tax (GST) as per the current indirect taxation policy, Government of India. Unless otherwise indicated, prices stated on our website are exclusive of applicable GST, any applicable value added tax (VAT) or other sales taxes. We are a business-to-consumer (B2C) service provider and we do not commit to provide any input tax credit on GST charged on subscription to our Research Service.

We may change the Subscription Fees and charges then in effect, or add new fees or charges which will take effect at the end of the client’s subscription period, by giving notice in advance and an opportunity to cancel renewal of the subscription.

Subscription Access & Renewal: Subscription to the Website commences immediately on the realisation of payment of the Subscription Fees. Subscriptions are set to be renewed automatically at the end of the subscription period.

Unless the client notifies us before the end of his/her subscription period, or the client cancels the auto-renewal mandate within the period specified by law, that the client does not wish to renew his/her subscription, the client’s subscription will renew for the period defined by the client’s subscription plan. We will charge the subscription using the same payment method that you previously used.

Although the client may notify to us his/her intention to his/her subscription, such notice will only take effect at the end of his/her then current subscription period, and he/she will not receive a refund other than as set out under Clause 8 in these Terms.

The client may notify us of his/her wish to cancel his/her subscription by sending an email to [email protected]. The client must provide at least 5 business days advance notice for this to be implemented.

Refunds: There can be no cancellation and refund of subscription fee paid once the subscription is active, other than as stated in Clause 8 of these Terms. If the client is entitled to a refund as specified under Clause 8 of these Terms, the RA will credit that refund to the card or other payment method used by the client to submit payment, unless it has expired - in which case the RA will contact the client to proceed with the refund. If we do issue a refund or credit due to circumstances outside the obligations specified under Clause 8, we are under no obligation to issue the same or a similar refund in the future.

General disclaimers: The recommendations made herein in the Research Services are expression of views and/or opinions and should not be deemed or construed to be advice for the purpose of purchase or sale of any security, nor a solicitation or offering on any investment/ trading opportunity on behalf of the company, AMC, insurance company, or issuer of security referred to herein.

The content and research reports generated by the RA does not constitute or is not intended to constitute an offer to buy or sell, or a solicitation to an offer to buy or sell financial products, units or securities.

The information/ opinion/ views mentioned in research reports or by the RA are not meant to serve as a professional guide to the client or recipients of this Report. The research report, recommendation, or any other content published by the RA do not assure or guarantee any minimum or fixed returns to the client or recipients of the reports/ recommendations/ content.

Use of this information is at the client’s own risk. The client must make his/ her own investment decisions based on his/her specific investment objective and financial position and using such independent advisors as he/she believes necessary. The services rendered by the RA are on a best-effort basis. All information in the content or research report of the RA is provided on an as is basis. Information is believed to be reliable but the RA does not warrant its completeness or accuracy and expressly disclaim all warranties and conditions of any kind, whether express or implied.

While due care has been taken to ensure that the disclosures, information, and opinions given are fair and reasonable, PrimeInvestor Financial Research Pvt Ltd and/or none of its officers, directors, partners, employees, agents, subsidiaries, affiliates or business associates shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information/ opinions/ views contained in the research report and recommendations that form part of the Research Service, and/or mails, social media or notifications issued by PrimeInvestor Financial Research Pvt Ltd or any other agency appointed/authorised by PrimeInvestor Financial Research Pvt Ltd. Returns and performance figures mentioned in the research report represent past performance and should not be constituted to be future returns or guaranteed returns.

Any agreements, transactions or other arrangements made between the client and any third party named on (or linked to from) the Website are at your own responsibility and entered into at your own risk. Any information that you receive via the Website, whether or not it is classified as “real time”, may have stopped being current by the time it reaches you. Market price information may be rounded up/down and therefore may not be entirely accurate.

The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research Services before onboarding.

History, present business and background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services.

Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made thereunder against the Research Analyst relating to Research Analyst services.

Details of the RA's associates: No associates.

Usage of Website Content: This Website is controlled and operated by the RA. All material, including research reports, recommendations, portfolios, ratings, lists of financial products, illustrations, statements, opinions, views, photographs, products, images, artwork, designs, text, graphics, logos, button icons, images, audio and video clips and software (collectively, “Content”) are protected by copyrights, trademarks and other intellectual property rights that are owned and controlled by the RA or by other parties that have licensed their material to us.

Except where otherwise agreed in writing with the RA, material on the Website is solely for the client’s personal, non-commercial use. Except as provided below, the client must not copy, reproduce, republish, upload, post, transmit or distribute such material in any way, including by e-mail or other electronic means and whether directly or indirectly and the client must not assist any other person to do so.

Without the prior written consent of the RA, modification of the materials, use of the materials on any other web site or networked computer environment or use of the materials for any purpose other than personal, non-commercial use is a violation of the copyrights, trademarks and other proprietary rights, and is prohibited. Any use for which the client receives any remuneration, whether in money or otherwise, is a commercial use for the purposes of these Terms.

The client may occasionally distribute a copy of a research report, or a portion of the same, from the Website in non-electronic form to a few individuals without charge, provided the client includes all copyright and other proprietary rights notices in the same form in which the notices appear, original source attribution, and the phrase “Used with permission from PrimeInvestor Financial Research Pvt. Ltd.”

While the client may occasionally download and store research reports or information from the Website for his/her personal use, he/she may not otherwise provide others with access to the same. The foregoing does not apply to any sharing functionality we provide through the Website that expressly allows the client to share Content or links to Content with others. In addition, the client may not use Content he/she has downloaded for personal use to develop or operate an automated trading system or for data or text mining.

The client agrees not to rearrange or modify the Content available through the Website. The client agrees not to display, post, frame, or scrape the Content for use on another website, app, blog, product or service, except as otherwise expressly permitted by these Terms. You agree not to create any derivative work based on or containing the research products and Content. The framing or scraping of or in-line linking to the Services or any Content contained thereon and/or the use of webcrawler, spidering or other automated means to access, copy, index, process and/or store any Content made available on or through the Services other than as expressly authorized by us is prohibited.

The client further agrees to abide by exclusionary protocols (e.g., Robots.txt, Automated Content Access Protocol (ACAP), etc.) that may be used in connection with the Research Services. The client may not access parts of the Research Services to which he/she is not authorized, or attempt to circumvent any restrictions imposed on your use or access of the Services.

As a general rule, the client may not use the Content, including without limitation, any Content made available through one of our RSS Feeds, in any commercial product or service, without our express written consent.

The client may not create apps, extensions, or other products and services that use our Content without our permission. The client may not aggregate or otherwise use our Content in a manner that could reasonably serve as a substitute for a subscription to the Website.

The client may not access or view the Services with the use of any scripts, extensions, or programs that alter the way the Services are displayed, rendered, or transmitted to you without our written consent.

The client agrees not to use the Services for any unlawful purpose. We reserve the right to terminate or restrict the client's access to the Website if, in our opinion, the client's use of the Services may violate any laws, regulations or rulings, infringe upon another person's rights or violate these Terms.

Prohibited content: The Website includes comments sections, blogs and other interactive features that allow interaction among clients and between clients and the RA. We call the information posted by or contributed by users “Contributed Content.” In the course of availing of the Research Services or uploading any post or comment on the Website, the client shall not post any Contributed Content that (i) contains nude, semi-nude, sexually suggestive photos, (ii) tends or is likely to abuse, harass, threaten, impersonate or intimidate other users of the Website and/or Research Services, (iii) is lascivious or appeals to the prurient interest or if its effect is such as to tend to deprave and corrupt persons who are likely to use or have access to the Website and/or Services, or (iv) otherwise violates, is prohibited or restricted by applicable law, rule or regulation, is offensive or illegal or violates the rights of, harms or threatens the safety of other users of the Website and/or Services (collectively “Prohibited Content”).

We reserve the right to cease to provide the client with the Research Services or access to the Website, or terminate your subscription, with immediate effect and without notice and liability, for violating these Terms, applicable law, rules or regulations and reserves the right to remove Prohibited Content which is in violation of these Terms, or is otherwise abusive, illegal or disruptive. The determination of whether any content constitutes Prohibited Content, violates these Terms, or is otherwise abusive illegal or disruptive, is subject to the sole determination of the Firm.

Changes to Research Services: We are constantly endeavouring to improve the quality of Research Services provided to our clients. Due to this, the form and nature of the Research Services provided may change from time to time without any prior notice to the client. We reserve the right to introduce and initiate new features, functionalities, components to the Website and/or Research Services and/or change, alter, modify, or discontinue existing ones without any prior notice to the client.

Warranty and liability disclaimer: The Website, Research Services, and all the materials and services, included on or otherwise made available to the client through this Website is provided by the RA on an “as is” and “as available” basis without any representation or warranties, express or implied except otherwise specified in writing. Without prejudice to the foregoing paragraph, the RA does not warrant that:

  • This Website and/or Research Services will be constantly available, or available at all;
  • The information on this Website or provided through the Research Services is complete, true, accurate or not misleading; or
  • The quality of any products, services, information, or other material that you obtain through the Website or Services will meet your expectations.

The RA, to the fullest extent permitted by law, disclaims all warranties, whether express or implied, including the warranty of merchantability, fitness for particular purpose and non-infringement. The RA makes no warranties about the accuracy, reliability, completeness, or timeliness of the Website, Research Services, Content, Contributed Content, Services, software, text, graphics and links.

The RA does not warrant that this Website, Research Services, information, content, materials, or any other material included on or otherwise made available to you through this Website, their servers, or electronic communication sent by the RA are free of viruses or other harmful components.

Nothing on this Website constitutes, or is meant to constitute, advice of any kind.

Indemnification: The client:

  1. Represents, warrants and covenants that no materials of any kind provided by him/her will:
    1. Violate, plagiarise, or infringe upon the rights of any third party, including copyright, trademark, privacy or other personal or proprietary rights; or
    2. Contain libellous, Prohibited Content or other unlawful material;
  2. Hereby agree to indemnify, defend and hold harmless the RA and all of the RA’s officers, directors, owners, agents, customers/clients, information providers, affiliates, licensors and licensees (collectively, the “Indemnified Parties”) from and against any and all liability and costs, including, without limitation, reasonable advocate’s fees, incurred by the Indemnified Parties in connection with any claim arising out of any breach by the client of these Terms or the foregoing representations, warranties and covenants. The client shall cooperate as fully as reasonably required in the defence of any such claim. The RA reserves the right, at its own expense, to assume the exclusive defence and control of any matter subject to indemnification by the client.

Applicable law: This Website, including the Content and Contributed Content and information contained herein, and the provision of Research Services shall be governed by the Securities and Exchange Board of India, laws of the Republic of India and the courts of Chennai, India which shall retain exclusive jurisdiction to entertain any proceedings in relation to any disputes arising out of the same. As such, the laws of India shall govern any transaction completed using this Website.

Information gathered and tracked: Information submitted or collected on the Website or pursuant to the use of the Services is stored in a database. Specifically, we store the username, name, e-mail address, contact number, as submitted or collected on our Website or through the provision of the Research Services. We may use such information to send out occasional promotional materials, including alerts on new Services available, or other promotional and marketing material relating to our clients and customers.

In accordance with the Information Technology Act 2000, the name and the details of the Grievance Officer at PrimeInvestor is provided below:

Mr. Srikanth Meenakshi
PrimeInvestor Financial Research Pvt. Ltd., Registered office: 659, 4th Avenue, D-Sector, Anna Nagar Western Extension, Chennai 600 101.
Email: [email protected]

11. Mandatory notice:

Clients shall be requested to go through Do’s and Don’ts while dealing with RA as specified in SEBI master circular no. SEBI/HO/MIRSD-POD-1/P/CIR/2024/49 dated May 21, 2024 or as may be specified by SEBI from time to time.

12. Optional Centralised Fee Collection Mechanism:

SEBI has operationalized a centralized fee collection mechanism for IA and RA. Under this mechanism, clients shall pay fees to IAs/RAs through a designated platform/portal administered by a recognized Administration and Supervision body. This is an optional mechanism for the registered entities. At this time, PrimeInvestor has opted out of this fee collection mechanism. Therefore, all subscription payments for the Research Services will be through the modes as specified in Clause 5 of these Terms.

Enter the OTP sent to (Edit)
By doing this you agree to our terms & conditions
Didn't receive OTP? Resend

comHi,

Registration Sucessful

Your 7-day Free Trial has started


comVerify your KYC

Unlock coupon 10% discount code

user icon
user icon
user icon
Skip for now

comHi,

Registration Sucessful

Your 7-day Free Trial has started


comKYC Verified

Discount Unlocked

com

*Applicable only on our Annual Subscription plans

Coupon will be auto applied during checkout

Skip for now
Have an account?
Login To Your Account
OR
Don’t have an account ? Register for free